Fatty Acid

Phosphatidylcholine

1,2-diacyl-sn-glycero-3-phosphocholine

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

500–2,000 mg

watchEffect Window

4-12 weeks for liver enzyme improvements.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Phosphatidylcholine is a major membrane phospholipid and a dietary choline source. It is used for liver fat handling and bile-related digestive support and to contribute to choline adequacy.

Evidence suggests benefits for some liver-related biomarkers and fat export pathways, relevant to fatty liver contexts. As a choline source, it supports acetylcholine synthesis and membrane integrity. Minority benefits include improved skin barrier measures and use in liposomal delivery systems. Effects depend on baseline choline intake, liver health, and formulation.

Major component of biological membranes serving as the body's primary delivery form of choline. Essential for acetylcholine synthesis, methylation pathways, and hepatic VLDL secretion to prevent fatty liver.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Supports liver recovery and prevents hepatic fat accumulation (NAFLD)
  • Major dietary choline source for acetylcholine synthesis and cell membrane integrity

Secondary Outcomes

  • Modest cognitive support via choline supply for acetylcholine
  • Effective as an emulsifier/liposomal carrier for other supplements

Safety

Contraindications and Interactions

Contraindications

  • Trimethylaminuria (genetic condition)

Side effects

  • GI upset (nausea, diarrhea, bloating)
  • Fishy body odor at high doses (trimethylamine production)

Interactions

  • Acetylcholinesterase inhibitors (additive cholinergic effects)
  • Anticholinergics (may reduce their efficacy)

Avoid if

  • Trimethylaminuria
  • On multiple cholinergic agents without monitoring

Evidence

Study-level References

phosphatidylcholine-SRC-001Review / Clinical summary
Sourceopen_in_new

Gundermann KJ, et al. "Activity of essential phospholipids (EPL) from soybean in liver diseases." Pharmacol Rep. 2011.

Population: Patients with liver diseases (NAFLD, ALD)

Dose protocol: 1,800 mg daily

Key findings: Essential phospholipids (highly purified phosphatidylcholine) showed positive effects on subjective symptoms, clinical findings, and biochemical markers of liver damage.

Paper content

Essential phospholipids (highly purified phosphatidylcholine) showed positive effects on subjective symptoms, clinical findings, and biochemical markers of liver damage.

phosphatidylcholine-SRC-002Randomized, placebo-controlled clinical trial.
Sourceopen_in_new

Kukharchuk VV, Ponomarenko EA, Lisitsa AV, et al. Vitaphospholip (water-soluble phosphatidylcholine) in the treatment of combined hyperlipidemia: a randomized, placebo-controlled clinical trial. Biomed Khim. 2025;71(5):364-374. doi:10.18097/PBMCR1619. PMID:41211734.

Population: Adults with combined hyperlipidemia.

Dose protocol: Water-soluble PC 500 mg twice daily versus placebo for 12 weeks in 100 patients with combined hyperlipidemia

Key findings: Non-HDL cholesterol decreased 13.2% vs 4.3% with placebo (p=0.001). Triglycerides decreased 0.7 mmol/L vs 0.1 (p=0.001). Target non-HDL-C achieved in 38.5% vs 4.9%. No serious adverse events.

Notes: Provides direct evidence that oral PC supplementation can improve lipid parameters, consistent with PC's known role in hepatic VLDL assembly and triglyceride export.

Paper content

This RCT tested oral water-soluble phosphatidylcholine (1000 mg/day) versus placebo for 12 weeks in 100 patients with combined hyperlipidemia. The PC group showed significant reductions in non-HDL cholesterol (13.2% vs 4.3%, p=0.001) and triglycerides (0.7 mmol/L decrease vs 0.1, p=0.001). Target non-HDL-C was achieved in 38.5% of the treatment group versus 4.9% on placebo. No serious adverse events were reported. This study provides direct evidence that oral PC supplementation can improve lipid parameters, consistent with PC's known role in hepatic VLDL assembly and triglyceride export.

phosphatidylcholine-SRC-003Meta-analysis of randomized controlled trials.
Sourceopen_in_new

Stremmel W, Vural H, Evliyaoglu O, Weiskirchen R. Delayed-Release Phosphatidylcholine Is Effective for Treatment of Ulcerative Colitis: A Meta-Analysis. Dig Dis. 2021;39(5):508-515. doi:10.1159/000514355. PMID:33440385.

Population: Patients with ulcerative colitis across 3 RCTs (160 patients).

Dose protocol: Delayed intestinal release 30% PC formulation versus placebo, pooled across 3 RCTs in UC patients

Key findings: Large pooled effect sizes for remission (OR 9.68), clinical improvement (OR 30.58), and endoscopic improvement (OR 36.73). However, a subsequent larger phase III trial was terminated for futility.

Notes: Instructive example of how small-trial meta-analytic signals can collapse under larger confirmatory data. The positive meta-analysis is real but the negative phase III weakens clinical applicability.

Paper content

This meta-analysis pooled 3 RCTs (n=160) of delayed-release phosphatidylcholine for ulcerative colitis. The pooled results showed large effect sizes for remission (OR 9.68), clinical improvement (OR 30.58), and endoscopic improvement (OR 36.73) versus placebo, with adverse events similar to placebo. However, a subsequent larger phase III trial (PMID 37806372) was terminated early for futility, which substantially weakens the overall evidence picture. The meta-analysis remains valuable as it demonstrates a strong signal from the earlier smaller trials, but the discordance with the phase III data means the clinical utility of delayed-release PC for UC is uncertain.

Guides

Setup

Help